Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer´s disease and its prevalence will continue to grow as the population ages, 1 doubling its number by 2030. 2 In Spain, the prevalence is estimated at 1.7%, giving a total of 69,571 patients. 3 The economic impact of the disease is enormous. In 2011, the annual European cost was estimated at €13.9 billion, and it is known to increase with the progression of the disease. 2 Longitudinal costs variations in relation to disease severity or symptoms has not been addressed in the literature, information much needed for estimating how medical spending occurs throughout the natural history of the disease. 2 
Objective
To describe the medical and non-medical direct costs of PD in relation to the total direct cost and its variation with disease severity during 4 years of follow-up.
Methods
A descriptive, observational, longitudinal study in PD patients belonging to the ELEP study (2007) (2008) (2009) (2010) .
Data on disease severity and use of resources were collected for three consecutive months, yearly, for 4 years. Direct medical (funded medical equipment, medications and medical assistance) and direct nonmedical costs (alternative care, home assistance, non-funded medical equipment and medications) for 4 years depending on severity by Hoehn and Yahr (HY) were described ( Figure 1 ). Costs were estimated by multiplying costs obtained from the database Oblikue (http://www.oblikue.com) and pharmacy costs from the BotPlus Web (https://botplusweb.portalfarma.com) by the number of resources used, updated to Spanish €, 2012.
Results
 198 patients were included. Average age: 63±11 years, 50% male, mean PD duration of 8±6 years. Mild (HYI-II) and moderate (HYIII) PD varied from 76% and 21% to 64% and 29%, respectively during follow-up ( Figure 2 (Figure 3 ). Given the small number of subjects in HY0 and HYV, stage, they were considered outliers and not included in the analysis. 
Conclusions
The economic burden of PD rises with duration and severity of the disease, progressively increasing the direct, medical and nonmedical costs. Besides to improve patients' HRQoL, therapies aimed at controlling the symptoms severity will favor a more efficient management of the disease. 
